GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000754811 | Prostate | Tumor | sex differentiation | 71/3246 | 276/18723 | 2.70e-04 | 2.24e-03 | 71 |
GO:190384413 | Prostate | Tumor | regulation of cellular response to transforming growth factor beta stimulus | 39/3246 | 131/18723 | 3.08e-04 | 2.48e-03 | 39 |
GO:004513712 | Prostate | Tumor | development of primary sexual characteristics | 60/3246 | 227/18723 | 3.65e-04 | 2.86e-03 | 60 |
GO:007217512 | Prostate | Tumor | epithelial tube formation | 39/3246 | 132/18723 | 3.66e-04 | 2.86e-03 | 39 |
GO:001701513 | Prostate | Tumor | regulation of transforming growth factor beta receptor signaling pathway | 38/3246 | 128/18723 | 3.89e-04 | 3.00e-03 | 38 |
GO:004001313 | Prostate | Tumor | negative regulation of locomotion | 94/3246 | 391/18723 | 4.20e-04 | 3.21e-03 | 94 |
GO:004886315 | Prostate | Tumor | stem cell differentiation | 55/3246 | 206/18723 | 4.81e-04 | 3.57e-03 | 55 |
GO:003033613 | Prostate | Tumor | negative regulation of cell migration | 84/3246 | 344/18723 | 4.95e-04 | 3.66e-03 | 84 |
GO:000224411 | Prostate | Tumor | hematopoietic progenitor cell differentiation | 34/3246 | 114/18723 | 7.00e-04 | 4.92e-03 | 34 |
GO:00032311 | Prostate | Tumor | cardiac ventricle development | 36/3246 | 123/18723 | 7.31e-04 | 5.08e-03 | 36 |
GO:001402012 | Prostate | Tumor | primary neural tube formation | 29/3246 | 94/18723 | 9.27e-04 | 6.10e-03 | 29 |
GO:00350511 | Prostate | Tumor | cardiocyte differentiation | 43/3246 | 156/18723 | 9.45e-04 | 6.20e-03 | 43 |
GO:002240916 | Prostate | Tumor | positive regulation of cell-cell adhesion | 70/3246 | 284/18723 | 1.06e-03 | 6.87e-03 | 70 |
GO:00902871 | Prostate | Tumor | regulation of cellular response to growth factor stimulus | 74/3246 | 304/18723 | 1.13e-03 | 7.22e-03 | 74 |
GO:000189313 | Prostate | Tumor | maternal placenta development | 14/3246 | 35/18723 | 1.30e-03 | 8.19e-03 | 14 |
GO:000328111 | Prostate | Tumor | ventricular septum development | 23/3246 | 71/18723 | 1.47e-03 | 9.08e-03 | 23 |
GO:000184312 | Prostate | Tumor | neural tube closure | 27/3246 | 88/18723 | 1.50e-03 | 9.25e-03 | 27 |
GO:003051111 | Prostate | Tumor | positive regulation of transforming growth factor beta receptor signaling pathway | 13/3246 | 32/18723 | 1.62e-03 | 9.79e-03 | 13 |
GO:190384611 | Prostate | Tumor | positive regulation of cellular response to transforming growth factor beta stimulus | 13/3246 | 32/18723 | 1.62e-03 | 9.79e-03 | 13 |
GO:006060612 | Prostate | Tumor | tube closure | 27/3246 | 89/18723 | 1.80e-03 | 1.06e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CIT | SNV | Missense_Mutation | rs779515686 | c.4130N>T | p.Pro1377Leu | p.P1377L | O14578 | protein_coding | deleterious(0) | benign(0.248) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
CIT | SNV | Missense_Mutation | | c.5132C>T | p.Ser1711Phe | p.S1711F | O14578 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
CIT | SNV | Missense_Mutation | novel | c.2482N>A | p.Glu828Lys | p.E828K | O14578 | protein_coding | deleterious(0.04) | possibly_damaging(0.628) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CIT | SNV | Missense_Mutation | | c.3097G>T | p.Val1033Leu | p.V1033L | O14578 | protein_coding | tolerated(0.08) | probably_damaging(0.978) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CIT | SNV | Missense_Mutation | rs747447396 | c.2839C>T | p.Arg947Cys | p.R947C | O14578 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CIT | SNV | Missense_Mutation | rs747447396 | c.2839N>T | p.Arg947Cys | p.R947C | O14578 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CIT | SNV | Missense_Mutation | | c.242N>T | p.Ser81Phe | p.S81F | O14578 | protein_coding | deleterious(0.02) | benign(0.17) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CIT | SNV | Missense_Mutation | novel | c.637N>T | p.His213Tyr | p.H213Y | O14578 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
CIT | SNV | Missense_Mutation | rs368981957 | c.5590N>A | p.Asp1864Asn | p.D1864N | O14578 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CIT | SNV | Missense_Mutation | novel | c.1771N>A | p.Glu591Lys | p.E591K | O14578 | protein_coding | tolerated(0.31) | benign(0.019) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |